Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy

Seminars in Cancer Biology

Volumn 32, Issue , 2015, Pages 3-9

  Vicente Dueñas, Carolina ^a,b   Hauer, Julia ^c   Ruiz Roca, Lucía ^a,b   Ingenhag, Deborah ^c   Rodríguez Meira, Alba ^a,b   Auer, Franziska ^c   Borkhardt, Arndt ^c   Sánchez García, Isidro ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Cancer stem cell; Mouse model; Oncogenes; Stem cells; Tumoral reprogramming

Indexed keywords

BIOLOGICAL MODEL; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; HUMAN; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; REVIEW; THEORETICAL MODEL; TUMOR GENE; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; MOUSE; NEOPLASMS; ONCOGENE;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; ONCOGENES;

EID: 84929953179     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.02.001     Document Type: Review

References (65)

1. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 1982, 79:3637-3640.
2. Goldfarb M., Shimizu K., Perucho M., Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 1982, 296:404-409.
3. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297:474-478.
4. Pulciani S., Santos E., Lauver A.V., Long L.K., Robbins K.C., Barbacid M. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci USA 1982, 79:2845-2849.
5. Santos E., Tronick S.R., Aaronson S.A., Pulciani S., Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 1982, 298:343-347.
6. Shih C., Weinberg R.A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982, 29:161-169.
7. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400(6743):468-472.
8. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000, 24:57-60.
9. Boxer R.B., et al. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586.
10. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science 2002, 297:63-64.
11. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
12. Chomel J.C., Bonnet M.L., Sorel N., Bertrand A., Meunier M.C., Fichelson S., et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011, 118:3657-3660.
13. Chu S., McDonald T., Lin A., Chakraborty S., Huang Q., Snyder D.S., et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011, 118:5565-5572.
14. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409.
15. Hamilton A., Helgason G.V., Schemionek M., Zhang B., Myssina S., Allan E.K., et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012, 119:1501-1510.
16. Kumari A., Brendel C., Hochhaus A., Neubauer A., Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012, 119:530-539.
17. Vicente-Duenas C., Romero-Camarero I., Cobaleda C., Sanchez-Garcia I. Function of oncogenes in cancer development: a changing paradigm. EMBO J 2013, 32(11):1502-1513.
18. Krizhanovsky V., Lowe S.W. Stem cells: the promises and perils of p53. Nature 2009, 460:1085-1086.
19. Perez-Caro M., Cobaleda C., Gonzalez-Herrero I., Vicente-Duenas C., Bermejo-Rodriguez C., Sanchez-Beato M., et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 2009, 28:8-20.
20. Papp B., Plath K. Epigenetics of reprogramming to induced pluripotency. Cell 2013, 152:1324-1343.
21. Vicente-Duenas C., Fontan L., Gonzalez-Herrero I., Romero-Camarero I., Segura V., Aznar M.A., et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci USA 2012, 109:10534-10539.
22. Vicente-Duenas C., Romero-Camarero I., Gonzalez-Herrero I., Alonso-Escudero E., Abollo-Jimenez F., Jiang X., et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 2012, 31:3704-3717.
23. Romero-Camarero I., Jiang X., Natkunam Y., Lu X., Vicente-Duenas C., Gonzalez-Herrero I., et al. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun 2013, 4:1338.
24. Riggi N., Suva M.L., De Vito C., Provero P., Stehle J.C., Baumer K., et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010, 24:916-932.
25. Garcia C.B., Shaffer C.M., Alfaro M.P., Smith A.L., Sun J., Zhao Z., et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 2012, 31:2323-2334.
26. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
27. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
28. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3(5):475-479.
29. Banito A., Rashid S.T., Acosta J.C., Li S., Pereira C.F., Geti I., et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009, 23:2134-2139.
30. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
31. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
32. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
33. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
34. Utikal J., Polo J.M., Stadtfeld M., Maherali N., Kulalert W., Walsh R.M., et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148.
35. Vicente-Duenas C., Romero-Camarero I., Garcia-Criado F.J., Cobaleda C., Sanchez-Garcia I. The cellular architecture of multiple myeloma. Cell Cycle 2012, 11(20):3715-3717.
36. Vicente-Duenas C., Perez-Caro M., Abollo-Jimenez F., Cobaleda C., Sanchez-Garcia I. Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle 2009, 8:1314-1318.
37. Abollo-Jimenez F., Jimenez R., Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010, 20(2):98-106.
38. Castellanos A., Vicente-Duenas C., Campos-Sanchez E., Cruz J.J., Garcia-Criado F.J., Garcia-Cenador M.B., et al. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol 2010, 20(2):93-97.
39. Vicente-Duenas C., Cobaleda C., Martinez-Climent J.A., Sanchez-Garcia I. MALT lymphoma meets stem cells. Cell Cycle 2012, 11(16):2961-2962.
40. Vicente-Duenas C., Gonzalez-Herrero I., Cenador M.B., Criado F.J., Sanchez-Garcia I. Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle 2012, 11(20):3896-3900.
41. Eminli S., Foudi A., Stadtfeld M., Maherali N., Ahfeldt T., Mostoslavsky G., et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009, 41(9):968-976.
42. Kim J.B., Sebastiano V., Wu G., Arauzo-Bravo M.J., Sasse P., Gentile L., et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009, 136(3):411-419.
43. Baens M., Fevery S., Sagaert X., Noels H., Hagens S., Broeckx V., et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006, 66(10):5270-5277.
44. Li Z., Wang H., Xue L., Shin D.M., Roopenian D., Xu W., et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009, 114(19):4158-4168.
45. Hamburger A., Salmon S.E. Primary bioassay of human myeloma stem cells. J Clin Invest 1977, 60:846-854.
46. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197(4302):461-463.
47. Cohnheim J. Ueber entzundung und eiterung. Pathol Anat Physiol Klin Med 1867, 40:1-79.
48. Becker A.J., Mc C.E., Till J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197:452-454.
49. Siminovitch L., McCulloch E.A., Till J.E. The distribution of colony-forming cells among spleen colonies. J Cell Physiol 1963, 62:327-336.
50. Till J.E., Mc C.E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-222.
51. Kleinsmith L.J., Pierce G.B. Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964, 24:1544-1551.
52. Rowley J.D., Letter A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405):290-293.
53. Fialkow P.J. Clonal origin of human tumors. Biochim Biophys Acta 1976, 458(3):283-321.
54. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292(5819):154-156.
55. Heisterkamp N., Stephenson J.R., Groffen J., Hansen P.F., de Klein A., Bartram C.R., et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306(5940):239-242.
56. Davis R.L., Weintraub H., Lassar A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51(6):987-1000.
57. Yaish P., Gazit A., Gilon C., Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242(4880):933-935.
58. Hunter T. Oncoprotein networks. Cell 1997, 88(3):333-346.
59. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999, 91(2):163-168.
60. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037.
61. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21(24):3214-3231.
62. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837.
63. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488(7412):527-530.
64. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337(6095):730-735.
65. Youssef K.K., Lapouge G., Bouvree K., Rorive S., Brohee S., Appelstein O., et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol 2012, 14:1282-1294.